Adenovirus-mediated p53 gene therapy reverses resistance of breast cancer cells to adriamycin

Anti-Cancer Drugs

Volumn 22, Issue 6, 2011, Pages 556-562

  Qi, Xiaodong ^a   Chang, Zhikun ^a   Song, Jin ^a   Gao, Gui ^a   Shen, Zheng ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

adriamycin; breast cancer cells; multidrug resistance; p53 tumor gene therapy

Indexed keywords

ADENOVIRUS VECTOR; DOXORUBICIN; GLYCOPROTEIN P; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER GENE THERAPY; CANCER RESISTANCE; CELL COUNT; CELL STRAIN MCF 7; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SENSITIVITY; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IC 50; MOUSE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TUMOR VOLUME; VIRAL GENE DELIVERY SYSTEM; WESTERN BLOTTING; WILD TYPE;

ADENOVIRIDAE; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; FLOW CYTOMETRY; GENE THERAPY; GENES, P53; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; P-GLYCOPROTEIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSPLANTATION, HETEROLOGOUS;

EID: 79958296357     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328345b4e7     Document Type: Article

References (19)

1. Wang L, Yang CP, Horwitz SB, Trail PA, Casazza AM. Reversal of the human murine multidrug-resistance phenotype with megestrol acetate. Cancer Chemother Pharmcol 1994; 34:96-102. (Pubitemid 24157972)
2. Kartner N, Riordan JR, Ling V. Cell surface P-glycoprotein associated with multidrug-resistance in mammalian cell lines. Science 1983; 221:1285-1288. (Pubitemid 13005502)
3. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, Olivier M. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 2007; 28:622-629. (Pubitemid 46744292)
4. Geisler S, Lonning PE, Aas T, Johnsen H, Fluge O, Haugen DF, et al. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res 2001; 61:2505-2512. (Pubitemid 32685830)
5. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, et al. P53 status and the efficacy of cancer therapy in vivo. Science 1994; 266:807-810. (Pubitemid 24359290)
6. Linn SC, Honkoop AH, Hoekman K, Van der Valk P, Pinedo HM. Giaccone G. p53 and P-glycoprotein are often co-expressed and are associated with poor prognosis in breast cancer. Br J Cancer 1996; 74:63-68. (Pubitemid 26231979)
7. Eisold S, Linnebacher M, Ryschich E, Antolovic D, Hinz U, Klar E, Schmidt J. The effect of adenovirus expressing wild-type p53 on 5-fluorouracil chemosensitivity is related to p53 status in pancreatic cancer cell lines. World J Gastroenterol 2004; 10:3583-3589. (Pubitemid 39619273)
8. Lai SL, Perng RP, Hwang J. P53 gene status modulates the chemosensitivity of non-small cell lung cancer cell. J Biomed Sci 2000; 7:64-70. (Pubitemid 30046573)
9. Song K, Cowan KH, Sinha BK. In vivo studies of adenovirus-mediated P53 gene therapy for cis-platinum-resistant human ovarian tumor xenografts. Oncol Res 1999; 11:153-159.
10. Ganjavi H, Gee M, Narendran A, Freedman MH, Malkin D. Adenovirusmediated p53 gene therapy in pediatric soft-tissue sarcoma cell lines: sensitization to cisplatin and doxorubicin. Cancer Gene Ther 2005; 12:397-406. (Pubitemid 40411199)
11. Ganjavi H, Gee M, Narendran A, Parkinson N, Krishnamoorthy M, Freedman MH, Malkin D. Adenovirus-mediated p53 gene therapy in osteosarcoma cell lines: sensitization to cisplatin and doxorubicin. Cancer Gene Ther 2006; 13:415-419.
12. Trock BJ, Leonessa F, Clarke R. Multidrug resistance in breast cancer: a meta-analysis of MDR1/P-gp expression and its possible functional significance. J Natl Cancer Inst 1997; 89:917-931. (Pubitemid 27282064)
13. Kuwashima Y, Uehara T, Kishi K. Immunohistochemical characterization of undifferentiated carcinomas of the ovary. J Cancer Res Clin Oncol 1994; 120:672.
14. Sowa Y, Sakai T. Gene-regulating chemoprevention against cancer as a model for 'molecular-targeting prevention' of cancer. Nippon Eiseigaku Zasshi 2003; 58:267-274.
15. Levine AJ. P53 the cellular gatekeeper for growth and division. Cell 1997; 88:323-331. (Pubitemid 27131374)
16. Miyake H, Hara I, Hara S, Arakawa S, Kamidono S. Synergistic chemosensitization and inhibition of tumor growth and metastasis adenovirus-mediated p53 gene transfer in human bladder cancer model. Urology 2000; 56:332-336. (Pubitemid 30495606)
17. Ameyar M, Shatrov V, Bouquet C, Capoulade C, Cai Z, Stancou R, et al. Adenovirus-mediated transfer of wild-type p53 gene sensitizes TNF resistant MCF7 derivatives to the cytotoxic effect of this cytokine: relationship with c-myc and Rb. Oncogene 1999; 18:5464-5472. (Pubitemid 29469234)
18. David GL, Yegnasubramanian S, Kumar A, Marchi VL, De Marzo AM, Lin X, et al. MDR1 promoter hypermethylation in MCF-7 human breast cancer cells: changes in chromatin structure induced by treatment with 5-Azacytidine. Cancer Biol Ther 2004; 3:540-548. (Pubitemid 41351125)
19. Sampath J, Sun DX, Kidd VJ, Grenet J, Gandhi A, Shapiro LH, et al. Mutant p53 cooperates with ETS and selectively up-regulates human MDR1 not MRP1. J Biol Chem 2001; 276:39359-39367.